Erkut Hasan Borazanci

15PUBLICATIONS
63CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsNanotoxicology, health and safetyEpidemiological methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Nov 26, 2025
Confirmatory Clinical Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma.

Patricio M Polanco, Tamas Gonda, Erkut Borazanci

|Apr 28, 2025
Retrospective analysis of capecitabine maintenance therapy in pancreatic ductal adenocarcinoma.

Jordan Powell, Alexa F Viniotis, Chase Irwin

|Jan 23, 2025
Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction.

Vincent Chung, Angela Alistar, Carlos Becerra

|Aug 27, 2024
Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study.

Erkut H Borazanci, Nathan Bahary, Vincent Chung

|Mar 27, 2023
A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas.

Manuel Hidalgo, Rocio Garcia-Carbonero, Kian-Huat Lim

|Nov 11, 2022
Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib.

Gehan Botrus, Denise Roe, Gayle S Jameson

Pageof 3

Frequent Collaborators

2 joint publications

Paul Oberstein

2 joint publications

Randall E Brand

1 joint publications

Benjamin Musher

1 joint publications

Nitya Nair